Carrier Screening Market by Product and Service, Type (Expanded Carrier (Predesigned, Customized), Targeted Disease Carrier), Medical Condition (Pulmonary, Hematological), Technology (Sequencing, PCR), End User, Region

Increasing emphasis on early disease detection and prevention is expected to drive the growth of the global carrier screening market.

The global carrier screening market size is expected to grow from USD 1.8 billion in 2019 to USD 4.0 billion by 2024, at a CAGR of 17.5% during the forecast period. Growth in the carrier screening market can primarily be attributed to factors such as increasing emphasis on early disease detection and prevention, the high risk of chromosomal abnormalities, and technological advancements in carrier screening, such as the introduction of expanded carrier screening panels. The increasing awareness of carrier screening is expected to provide a wide range of growth opportunities for players in the market.

The expanded carrier screening segment is expected to grow at the highest CAGR during the forecast period.

On the basis of type, the carrier screening market is segmented into targeted disease screening and expanded carrier screening, which includes predesigned and customized carrier screening panel testing. The growth of this segment can be attributed to factors such as the increasing use of new high-throughput technologies such as sequencing & microarrays and recommendations for the use of expanded carrier screening.

In 2018, the hospitals segment accounted for the largest share of the carrier screening market.

On the basis of end-user, the carrier screening market is segmented into hospitals, physician offices and clinics, reference laboratories, and other end users (blood banks, donor banks, community clinic laboratories, and non-profit organizations). In 2018, hospitals formed the largest end-user segment in the carrier screening market. Generally, gynecologists suggest couples to undergo carrier screening tests before and after pregnancy. In such cases, it is observed that gynecologists give reference for genetic counselors, who generally practice at hospitals. As a result, the awareness about hospital-based carrier screening tests is higher among patients than those offered at reference laboratories or at physician offices and clinics. Also, hospitals offer flexibility to patients in terms of sample collection, scheduling specimen pickups, and rapid turnaround time to produce results.

North America to grow at the highest CAGR during the forecast period.

North America is expected to grow at the highest rate during the forecast period, followed by Europe. This growth can be attributed to several factors, such as the presence of well-established healthcare systems in the US and Canada, wide access to advanced screening techniques (such as DNA sequencing), recommendations for carrier screening, high and growing demand for the early detection of genetic disorders among the population, availability of mass genetic testing programs, increasing number of awareness campaigns, and the high incidence of chromosomal disorders.

In-depth interviews were conducted with chief executive officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the carrier screening market.

By Respondent Type: Supply-side: 80%, Demand-side: 20%
By Designation: C-level Executives: 27%, Directors: 18%, and Others: 55%
By Region: North America: 50%, Europe: 20%, APAC: 15%, and RoW: 15%

The carrier screening market comprises major players such as Illumina (US), Natera (US), Fulgent Genetics (US), Sema4 (US), Invitae (US), and LabCorp (US). The study includes an in-depth competitive analysis of these key players in the market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:

The market study covers the carrier screening market across various segments. It aims at estimating the market size and the growth potential of this market across different segments based on the product & service, medical conditions, technology, condition, type, end-user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall carrier screening market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, opportunities, and challenges.

Frequently Asked Questions about the Global Carrier Screening Market

What is the estimated value of the Global Carrier Screening Market?

The Global Carrier Screening Market was estimated to be valued at $1.8 billion in 2019.

What is the growth rate of the Global Carrier Screening Market?

The growth rate of the Global Carrier Screening Market is 17.3%, with an estimated value of $4 billion by 2024.

What is the forecasted size of the Global Carrier Screening Market?

The Global Carrier Screening Market is estimated to be worth $4 billion by 2024.

Who are the key companies in the Global Carrier Screening Market?

Key companies in the Global Carrier Screening Market include Eurofins Scientific, Invitae Corporation, Opko Health, Fulgent Genetics Inc, Quest Diagnostics Incorporated, Sema4, Myriad Genetics, Illumina Inc, Thermo Fisher Scientific Inc and Luminex Corporation.

Report Attribute	Details
No. of Pages	149
Published	November 2019
Forecast Period	2019 - 2024
Estimated Market Value ( USD ) in 2019	$ 1.8 billion
Forecasted Market Value ( USD ) by 2024	$ 4 billion
Compound Annual Growth Rate	17.3%
Regions Covered	Global
No. of Companies Mentioned	20

1 Introduction

1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.4 Years Covered for the Study
1.5 Currency
1.6 Limitations
1.7 Stakeholders

2 Research Methodology

2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Secondary Sources
2.1.2 Primary Data
2.2 Market Estimation Methodology
2.2.1 Revenue Mapping-Based Market Estimation
2.2.2 Primary Research Validation
2.3 Data Triangulation
2.4 Research Assumptions
2.5 Research Limitations

3 Executive Summary

4 Premium Insights

4.1 Market Overview
4.2 Europe: Market Share, By Type and Country (2019)
4.3 Market, By Medical Condition
4.4 Market, By Technology (USD Million) (2019 vs 2024)
4.5 Market, By End User (USD Million) (2019 vs 2024)

5 Market Overview

5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Emphasis on Early Disease Detection and Prevention
5.2.1.2 High Risk of Chromosomal Abnormalities With Advancing Maternal Age
5.2.1.3 Technological Advancements
5.2.2 Opportunities
5.2.2.1 Increasing Awareness of Carrier Screening
5.2.3 Challenges
5.2.3.1 Lack of Skilled Professionals
5.2.3.2 Lack of Standard Guidelines for Carrier Screening

6 Carrier Screening Market, By Product & Service

6.1 Introduction
6.2 Services
6.2.1 Rising Number of Accredited Laboratories is the Major Indicator of Market Growth
6.3 Products
6.3.1 Expanding Use of Carrier Screening Tests has Driven Growth in the Products Market

7 Carrier Screening Market, By Type

7.1 Introduction
7.2 Expanded Carrier Screening
7.2.1 Predesigned Panel Testing
7.2.1.1 Predesigned Panel Testing Accounts for the Largest Market Share
7.2.2 Customized Panel Testing
7.2.2.1 Customized Panels Allow for Specific Sets of Conditions to Be Screened
7.3 Targeted Disease Carrier Screening
7.3.1 Introduction of Panels Capable of Simultaneously Screening Multiple Conditions has Driven Market Growth

8 Carrier Screening Market, By Medical Condition

8.1 Introduction
8.2 Pulmonary Conditions
8.2.1 Increasing Awareness About Cystic Fibrosis and Customized Services Likely to Boost Market Growth
8.2.2 Carrier Screening Products/Services for Cystic Fibrosis
8.3 Hematological Conditions
8.3.1 Rising Prevalence of Hematological Disorders has Increased the Use of Expanded Carrier Screening Panels
8.4 Neurological Conditions
8.4.1 Growing Number of Awareness Programs for Neurological Screening and Presence of Targeted Screening Panels to Support Market Growth
8.4.2 Global Prevalence of Neurological Conditions
8.4.3 Carrier Screening Products/Services for Neurological Conditions
8.5 Other Medical Conditions

9 Carrier Screening Market, By Technology

9.1 Introduction
9.2 Dna Sequencing
9.2.1 Increasing Need to Detect Multiple Genes Simultaneously is Driving Demand for NGS
9.3 Polymerase Chain Reaction
9.3.1 Rising Number of Carrier Screening Tests for Targeted Chromosomal Conditions has Increased the Use of PCR
9.4 Microarrays
9.4.1 Clinical Validity of Microarray in Carrier Screening has Increased Its Use in Reference Laboratories
9.5 Other Technologies

10 Carrier Screening Market, By End User

10.1 Introduction
10.2 Hospitals
10.2.1 Hospitals Formed the Largest End-User Segment in the Market
10.3 Reference Laboratories
10.3.1 Advantages Offered By Reference Laboratories in Terms of Service Costs and Turnaround Time to Support Market Growth
10.4 Physician Offices and Clinics
10.4.1 Large Number of Physician Offices and Clinics are Outsourcing Carrier Screening Testing Services
10.5 Other End Users

11 Carrier Screening Market, By Region

11.1 Introduction
11.2 North America
11.2.1 US
11.2.1.1 US Was the Largest Market for Carrier Screening Products and Services Globally in 2018
11.2.2 Canada
11.2.2.1 Awareness Programs, Campaigns, and Conferences are Promoting Carrier Screening in Canada
11.3 Europe
11.3.1 Germany
11.3.1.1 Rising Prevalence of Genetic Disorders to Support Market Growth in Germany
11.3.2 UK
11.3.2.1 High Incidence of Genetic Abnormalities to Drive the Demand for Preconception Screening in the UK
11.3.3 France
11.3.3.1 Government Initiatives Focused on Genomics Research are Expected to Support the Growth of the Market in France
11.3.4 RoE
11.4 Asia Pacific
11.4.1 Increasing Government Support Will Aid the Growth of This Market
11.5 RoW
11.5.1 The RoW Market is Significantly Smaller Than Other Regional Markets

12 Competitive Landscape

12.1 Introduction
12.2 Market Ranking Analysis
12.3 Competitive Leadership Mapping (2019)
12.3.1 Vendor Inclusion Criteria
12.3.2 Visionary Leaders
12.3.3 Innovators
12.3.4 Dynamic Differentiators
12.3.5 Emerging Companies
12.4 Competitive Scenario
12.4.1 Key Product and Service Launches
12.4.2 Key Acquisitions
12.4.3 Key Partnerships and Collaborations

13 Company Profile
(Business Overview, Products Offered, Recent Developments, MnM View)*
13.1 Eurofins Scientific
13.2 Invitae Corporation
13.3 Opko Health
13.4 Fulgent Genetics Inc
13.5 Quest Diagnostics Incorporated
13.6 Sema4
13.7 Myriad Genetics
13.8 Illumina Inc
13.9 Thermo Fisher Scientific Inc
13.10 Luminex Corporation
13.11 Natera Inc
13.12 Laboratory Corporation of America Holdings
13.13 BGI
13.14 Gene By Gene
13.15 Progenity
13.16 Otogenetics Corporation
13.17 Centogene
13.18 Pathway Genomics
13.19 Medgenome
13.20 True Health

*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.

14 Appendix

14.1 Discussion Guide
14.2 Knowledge Store: Subscription Portal
14.3 Available Customizations
14.4 Related Reports
14.5 Author DetailsList of Tables (127 Tables)

Table 1 Market, By Product & Service, 2017–2024 (USD Million)
Table 2 Carrier Screening Services Market, By Region, 2017–2024 (USD Million)
Table 3 North America: Carrier Screening Services Market, By Country, 2017–2024 (USD Million)
Table 4 Europe: Carrier Screening Services Market , By Country, 2017–2024 (USD Million)
Table 5 Carrier Screening Products Market, By Region, 2017–2024 (USD Million)
Table 6 North America: Carrier Screening Products Market, By Country, 2017–2024 (USD Million)
Table 7 Europe: Carrier Screening Products Market, By Country, 2017–2024 (USD Million)
Table 8 Market, By Type, 2017–2024 (USD Million)
Table 9 Expanded Carrier Screening Market, By Type, 2017–2024 (USD Million)
Table 10 Expanded Carrier Screening Market, By Region, 2017–2024 (USD Million)
Table 11 North America: Expanded Carrier Screening Market, By Country, 2017–2024 (USD Million)
Table 12 Europe: Expanded Carrier Screening Market, By Country, 2017–2024 (USD Million)
Table 13 Predesigned Panel Testing Market, By Region, 2017–2024 (USD Million)
Table 14 North America: Predesigned Panel Testing Market, By Country, 2017–2024 (USD Million)
Table 15 Europe: Predesigned Panel Testing Market, By Country, 2017–2024 (USD Million)
Table 16 Customized Panel Testing Market, By Region, 2017–2024 (USD Million)
Table 17 North America: Customized Panel Testing Market, By Country, 2017–2024 (USD Million)
Table 18 Europe: Customized Panel Testing Market, By Country, 2017–2024 (USD Million)
Table 19 Targeted Disease Carrier Screening Market, By Region, 2017–2024 (USD Million)
Table 20 North America: Targeted Disease Carrier Screening Market, By Country, 2017–2024 (USD Million)
Table 21 Europe: Targeted Disease Carrier Screening Market, By Country, 2017–2024 (USD Million)
Table 22 Market, By Medical Condition, 2017–2024 (USD Million)
Table 23 Live Birth Incidence of Cystic Fibrosis
Table 24 Market for Pulmonary Conditions, By Region, 2017–2024 (USD Million)
Table 25 North America: Market for Pulmonary Conditions, By Country, 2017–2024 (USD Million)
Table 26 Europe: Market for Pulmonary Conditions, By Country, 2017–2024 (USD Million)
Table 27 Market for Hematological Conditions, By Region, 2017–2024 (USD Million)
Table 28 North America: Market for Hematological Conditions, By Country, 2017–2024 (USD Million)
Table 29 Europe: Market for Hematological Conditions, By Country, 2017–2024 (USD Million)
Table 30 Market for Neurological Conditions, By Region, 2017–2024 (USD Million)
Table 31 North America: Market for Neurological Conditions, By Country, 2017–2024 (USD Million)
Table 32 Europe: Market for Neurological Conditions, By Country, 2017–2024 (USD Million)
Table 33 Market for Other Medical Conditions, By Region, 2017–2024 (USD Million)
Table 34 North America: Market for Other Medical Conditions, By Country, 2017–2024 (USD Million)
Table 35 Europe: Market for Other Medical Conditions, By Country, 2017–2024 (USD Million)
Table 36 Market, By Technology, 2017–2024 (USD Million)
Table 37 Comparison of Sequencing Technologies Used By Market Players
Table 38 Market for Dna Sequencing, By Region, 2017–2024 (USD Million)
Table 39 North America: Market for Dna Sequencing, By Country, 2017–2024 (USD Million)
Table 40 Europe: Market for Dna Sequencing, By Country, 2017–2024 (USD Million)
Table 41 Comparison of PCR Technologies Used By Market Players
Table 42 Market for PCR, By Region, 2017–2024 (USD Million)
Table 43 North America: Market for PCR, By Country, 2017–2024 (USD Million)
Table 44 Europe: Market for PCR, By Country, 2017–2024 (USD Million)
Table 45 Comparison of Microarray Technologies Used By Market Players
Table 46 Market for Microarrays, By Region, 2017–2024 (USD Million)
Table 47 North America: Market for Microarrays, By Country, 2017–2024 (USD Million)
Table 48 Europe: Market for Microarrays, By Country, 2017–2024 (USD Million)
Table 49 Market for Other Technologies, By Region, 2017–2024 (USD Million)
Table 50 North America: Market for Other Technologies, By Country, 2017–2024 (USD Million)
Table 51 Europe: Market for Other Technologies, By Country, 2017–2024 (USD Million)
Table 52 Market, By End User, 2017–2024 (USD Million)
Table 53 Market for Hospitals, By Region, 2017–2024 (USD Million)
Table 54 North America: Market for Hospitals, By Country, 2017–2024 (USD Million)
Table 55 Europe: Market for Hospitals, By Country, 2017–2024 (USD Million)
Table 56 Market for Reference Laboratories, By Region, 2017–2024 (USD Million)
Table 57 North America: Market for Reference Laboratories, By Country, 2017–2024 (USD Million)
Table 58 Europe: Market for Reference Laboratories, By Country, 2017–2024 (USD Million)
Table 59 Market for Physician Offices and Clinics, By Region, 2017–2024 (USD Million)
Table 60 North America: Market for Physician Offices and Clinics, By Country, 2017–2024 (USD Million)
Table 61 Europe: Market for Physician Offices and Clinics, By Country, 2017–2024 (USD Million)
Table 62 Market for Other End Users, By Region, 2017–2024 (USD Million)
Table 63 North America: Market for Other End Users, By Country, 2017–2024 (USD Million)
Table 64 Europe: Market for Other End Users, By Country, 2017–2024 (USD Million)
Table 65 Market, By Region, 2017–2024 (USD Million)
Table 66 North America: Market, By Product & Service, 2017–2024 (USD Million)
Table 67 North America: Market, By Type, 2017–2024 (USD Million)
Table 68 North America: Expanded Market, By Type, 2017–2024 (USD Million)
Table 69 North America: Market, By Technology, 2017–2024 (USD Million)
Table 70 North America: Market, By Medical Condition, 2017–2024 (USD Million)
Table 71 North America: Carrier Screening Market, By End User, 2017–2024 (USD Million)
Table 72 North America: Market, By Country, 2017–2024 (USD Million)
Table 73 US: Market, By Product & Service, 2017–2024 (USD Million)
Table 74 US: Market, By Type, 2017–2024 (USD Million)
Table 75 US: Expanded Carrier Screening Market, By Type, 2017–2024 (USD Million)
Table 76 US: Market, By Technology, 2017–2024 (USD Million)
Table 77 US: Market, By Medical Condition, 2017–2024 (USD Million)
Table 78 US: Market, By End User, 2017–2024 (USD Million)
Table 79 Canada: Market, By Product & Service, 2017–2024 (USD Million)
Table 80 Canada: Market, By Type, 2017–2024 (USD Million)
Table 81 Canada: Expanded Carrier Screening Market, By Type, 2017–2024 (USD Million)
Table 82 Canada: Market, By Technology, 2017–2024 (USD Million)
Table 83 Canada: Market, By Medical Condition, 2017–2024 (USD Million)
Table 84 Canada: Market, By End User, 2017–2024 (USD Million)
Table 85 Europe: Market, By Product & Service, 2017–2024 (USD Million)
Table 86 Europe: Market, By Type, 2017–2024 (USD Million)
Table 87 Europe: Expanded Carrier Screening Market, By Type, 2017–2024 (USD Million)
Table 88 Europe: Market, By Technology, 2017–2024 (USD Million)
Table 89 Europe: Market, By Medical Condition, 2017–2024 (USD Million)
Table 90 Europe: Market, By End User, 2017–2024 (USD Million)
Table 91 Europe: Market, By Country, 2017–2024 (USD Million)
Table 92 Germany: Market, By Product & Service, 2017–2024 (USD Million)
Table 93 Germany: Market, By Type, 2017–2024 (USD Million)
Table 94 Germany: Expanded Carrier Screening Market, By Type, 2017–2024 (USD Million)
Table 95 Germany: Market, By Technology, 2017–2024 (USD Million)
Table 96 Germany: Market, By Medical Condition, 2017–2024 (USD Million)
Table 97 Germany: Market, By End User, 2017–2024 (USD Million)
Table 98 UK: Market, By Product & Service, 2017–2024 (USD Million)
Table 99 UK: Market, By Type, 2017–2024 (USD Million)
Table 100 UK: Expanded Carrier Screening Market, By Type, 2017–2024 (USD Million)
Table 101 UK: Market, By Technology, 2017–2024 (USD Million)
Table 102 UK: Market, By Medical Condition, 2017–2024 (USD Million)
Table 103 UK: Market, By End User, 2017–2024 (USD Million)
Table 104 France: Market, By Product & Service, 2017–2024 (USD Million)
Table 105 France: Market, By Type, 2017–2024 (USD Million)
Table 106 France: Expanded Carrier Screening Market, By Type, 2017–2024 (USD Million)
Table 107 France: Market, By Technology, 2017–2024 (USD Million)
Table 108 France: Market, By Medical Condition, 2017–2024 (USD Million)
Table 109 France: Market, By End User, 2017–2024 (USD Million)
Table 110 RoE: Market, By Product & Service, 2017–2024 (USD Million)
Table 111 RoE: Market, By Type, 2017–2024 (USD Million)
Table 112 RoE: Expanded Carrier Screening Market, By Type, 2017–2024 (USD Million)
Table 113 RoE: Market, By Technology, 2017–2024 (USD Million)
Table 114 RoE: Market, By Medical Condition, 2017–2024 (USD Million)
Table 115 RoE: Market, By End User, 2017–2024 (USD Million)
Table 116 Asia Pacific: Market, By Product & Service, 2017–2024 (USD Million)
Table 117 Asia Pacific: Market, By Type, 2017–2024 (USD Million)
Table 118 Asia Pacific: Expanded Carrier Screening Market, By Type, 2017–2024 (USD Million)
Table 119 Asia Pacific: Market, By Technology, 2017–2024 (USD Million)
Table 120 Asia Pacific: Market, By Medical Condition, 2017–2024 (USD Million)
Table 121 Asia Pacific: Market, By End User, 2017–2024 (USD Million)
Table 122 RoW: Market, By Product & Service, 2017–2024 (USD Million)
Table 123 RoW: Market, By Type, 2017–2024 (USD Million)
Table 124 RoW: Expanded Carrier Screening Market, By Type, 2017–2024 (USD Million)
Table 125 RoW: Market, By Technology, 2017–2024 (USD Million)
Table 126 RoW: Market, By Medical Condition, 2017–2024 (USD Million)
Table 127 RoW: Market, By End User, 2017–2024 (USD Million)List of Figures (32 Figures)

Figure 1 Research Design
Figure 2 Breakdown of Primaries: Carrier Screening Market
Figure 3 Research Methodology: Hypothesis Building
Figure 4 Market Size Estimation: Market
Figure 5 Data Triangulation Methodology
Figure 6 Market, By Technology, 2018
Figure 7 Market, By Product & Service, 2018
Figure 8 Market, By Medical Condition, 2018
Figure 9 Market, By End User, 2018
Figure 10 Geographical Snapshot of the Market
Figure 11 Rising Global Genetic Disease Burden and Increasing Focus on Early Carrier Screening are Driving the Market
Figure 12 Germany Dominates the European Market for Carrier Screening
Figure 13 Pulmonary Conditions Accounted for Largest Market Share in 2018
Figure 14 Dna Sequencing Segment Dominates the Carrier Screening Market
Figure 15 Hospitals to Hold the Largest Market Share During 2019–2024
Figure 16 Carries Screening Market: Drivers, Opportunities, and Challenges
Figure 17 Market: Geographic Growth Opportunities
Figure 18 North America: Market Snapshot
Figure 19 Asia Pacific: Market Snapshot
Figure 20 Rank of Companies in the Market, 2018
Figure 21 MnM Dive-Vendor Comparison Matrix: Market
Figure 22 Eurofins Scientific: Company Snapshot (2018)
Figure 23 Invitae: Company Snapshot (2018)
Figure 24 Opko Health: Company Snapshot (2018)
Figure 25 Fulgent Genetics: Company Snapshot (2018)
Figure 26 Quest Diagnostics: Company Snapshot (2018)
Figure 27 Myriad Genetics: Company Snapshot (2018)
Figure 28 Illumina: Company Snapshot (2018)
Figure 29 Thermo Fisher Scientific: Company Snapshot (2018)
Figure 30 Luminex: Company Snapshot (2018)
Figure 31 Natera: Company Snapshot (2018)
Figure 32 Labcorp: Company Snapshot (2018)